Table 1.

Association of PinX1 expression with patient’s clinicopathological features in NSCLC

Variable	Learning cohort				Validation cohort
	Cases	Negative expression (%)	Positive expression (%)	P-value*	Cases	Negative expression (%)	Positive expression (%)	P-value*
Age(years)
<56a	42	21(50%)	21(50%)	0.068	22	13(59.1%)	9(40.9%)	0.443
≥56a	51	35(68.6%)	16(31.4%)		29	14(48.3%)	15(51.7%)
Gender
Male	61	39(63.9%)	22(36.1%)	0.312	35	17(48.6%)	18(51.4%)	0.355
Female	32	17(53.1)	15(46.9%)		16	10(62.5)	6(37.5%)
Smoking Condition
Smoker	42	32(76.2%)	10(23.8%)	0.004	20	16(80%)	4(20%)	0.002
Nonsmoker	51	24(47.1%)	27(52.9%)		31	11(35.5%)	20(64.5%)
WHO grade
G1	28	18(64.3%)	10(35.7%)	0.708	16	9(56.2%)	7(43.8%)	0.843
G2	37	22(62.2%)	15(37.8%)		20	11(55%)	9(45%)
G3	28	16(57.1%)	12(42.9%)		15	7(46.7%)	8(53.3%)
Histological Type
Squamous cell carcinoma	37	29(78.4%)	8(21.6%)	0.002	22	16(72.7%)	6(27.3%)	0.046
Adenocarcinoma	46	25(54.3%)	21(45.7%)		23	9(39.1%)	14(60.9%)
Others	10	2(25%)	8(75%)		6	2(33.3%)	4(77.7%)
T stage
T1-T2	38	15(39.5%)	23(60.5%)	0.001	18	4(22.2%)	14(88.8%)	0.001
T3-T4	55	41(74.5%)	14(25.5%)		33	23(69.7%)	10(30.3%)
N stage
N0	26	9(34.6%)	15(57.7%)	0.005	16	5(31.2%)	11(68.8%)	0.036
N1-N3	67	47(70.1%)	22(29.9%)		35	22(62.9%)	13(37.1%)
M stage
M0	66	45(68.2%)	21(31.8%)	0.014	35	14(40%)	21(60%)	0.006
M1	27	11(40.7%)	16(59.3%)		16	13(81.2%)	3(18.8%)
TNM stage
I-II	25	6(24%)	19(76%)	0.000	14	4(28.6%)	10(71.4%)	0.032
III-IV	68	50(73.5%)	18(26.5%)		37	23(62.2%)	14(37.8%)

*Chi-square test; ^aMean age; T tumor, N node, M metastases